GlaxoSmithKline Pharmaceuticals Limited Share Price NSE India S.E.

Equities

GLAXO

INE159A01016

Pharmaceuticals

Market Closed - NSE India S.E. 08:17:11 18/05/2024 BST 5-day change 1st Jan Change
2,360 INR +3.17% Intraday chart for GlaxoSmithKline Pharmaceuticals Limited +18.02% +24.31%

Financials

Sales 2024 34.54B 415M 32.66B Sales 2025 * 36.49B 438M 34.51B Capitalization 388B 4.66B 367B
Net income 2024 5.9B 70.86M 5.58B Net income 2025 * 7.68B 92.21M 7.26B EV / Sales 2024 9.53 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 10.6 x
P/E ratio 2024
55.8 x
P/E ratio 2025 *
50.6 x
Employees 3,680
Yield 2024 *
1.32%
Yield 2025 *
1.38%
Free-Float 24.42%
More Fundamentals * Assessed data
Dynamic Chart
GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
GlaxoSmithKline Pharmaceuticals Limited Recommends Dividend for the Year Ended 31 March 2024, Payable on and After 1 July 2024 CI
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Drugmaker Abbott India posts Q4 profit rise on higher sales RE
Glaxosmithkline Pharmaceuticals Limited Receives an Order from Maharashtra GST authorities CI
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology RE
GlaxoSmithKline Pharmaceuticals Limited Receives Orders from Government Authorities CI
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14% MT
Glaxosmithkline Pharmaceuticals Limited Appoints Aparajita Mukherjee Rajput, Technology Lead CI
GlaxoSmithKline Pharmaceuticals Sees Sharp Decline in Fiscal Q3 Consolidated Net Profit MT
GSK India arm's Q3 profit falls on government price cap RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Sunder Ramachandran as Head of Commercial Excellence, Effective 12 January 2024 CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Abhinav Kashyap as Pharma Technology Lead CI
More news
1 day+3.17%
1 week+18.02%
Current month+13.07%
1 month+24.97%
3 months+4.60%
6 months+43.18%
Current year+24.31%
More quotes
1 week
1 967.80
Extreme 1967.8
2 401.35
1 month
1 854.00
Extreme 1854
2 401.35
Current year
1 842.05
Extreme 1842.05
2 524.00
1 year
1 277.10
Extreme 1277.1
2 524.00
3 years
1 227.00
Extreme 1227
2 524.00
5 years
962.65
Extreme 962.65
2 524.00
10 years
962.65
Extreme 962.65
2 524.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 30/11/22
Director of Finance/CFO - 31/03/22
Compliance Officer - -
Members of the board TitleAgeSince
Chairman 70 31/03/19
Director/Board Member 64 15/05/22
Director/Board Member 74 29/03/15
More insiders
Date Price Change Volume
18/05/24 2,360 +3.17% 126 099
17/05/24 2,287 +13.08% 1,198,663
16/05/24 2,022 +1.68% 110,541
15/05/24 1,989 -0.27% 84,411
14/05/24 1,994 -0.25% 36,943

Delayed Quote NSE India S.E., May 18, 2024 at 08:17 am

More quotes
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2,292 INR
Average target price
2,141 INR
Spread / Average Target
-6.56%
Consensus